Tiffany A. Traina, MD
New York, New York
Vice Chair, Oncology Care, Department of Medicine
Section Head, Triple Negative Breast Cancer Clinical Research Program
Memorial Sloan Kettering Cancer Center
New York, New York
Targeting alternative steroid receptors in triple-negative breast cancer.
Triple-negative breast cancer (TNBC) refers to a diverse group of breast cancers that lack the typical hormone receptors found in most breast cancers, estrogen receptor (ER), progesterone receptor, as well as the HER2 protein—and are thus not candidates for endocrine or anti-HER2 therapies. The standard of care remains chemotherapy-based treatment. In search of other therapeutic targets, studies found that 12 to 50 percent of TNBC harbor the androgen receptor (AR) or signs of AR activation. When AR-positive TNBC recur they are likely to also have high levels of the glucocorticoid receptor (GR), which may work with AR to drive tumor growth. With this information, Drs. Tiffany Traina, Rita Nanda, and their teams designed a clinical trial to test the use of AR and GR-targeting drugs on patient with AR-positive, metastatic TNBC.
The study, which will ultimately enroll 201 patients, is anticipated to open in late 2021. It will assess the ability of the AR-targeting enzalutamide, or enzalutamide in combination with GR-targeting mifepristone, to extend progression free survival when compared with chemotherapy.
Tiffany A. Traina, MD, is Vice Chair of the Department of Medicine and has been a medical oncologist on the Breast Medicine Service since 2006. She is also the Section Head of the Triple Negative Breast Cancer Clinical Research Program in which she works to develop new treatment options for this sub-type of breast cancer. Dr. Traina serves on the Triple Negative Breast Cancer working group panel of the Translational Breast Cancer Research Collaborative, and has lectured internationally, presenting her research findings at forums including the annual San Antonio Breast Cancer Symposium and the annual meeting of the American Society of Clinical Oncology (ASCO). She is a member of the New York Metropolitan Breast Cancer Group and serves on the editorial board of the European Journal of Clinical & Medical Oncology.
When you give to BCRF, you're funding critical hours in the lab. More time for research means longer, healthier lives for the ones we love.